ABIVAX to present at the BIO Europe 2015 conference and at the Deutsches Eigenkapitalforum

Paris, October 15, 2015 – ABIVAX (Euronext Paris: FR0012333284 – ABVX), a publicly traded, clinical stage biotech company developing and commercializing therapeutic anti-viral drugs and vaccines, today announced the participation of its CEO, Prof. Dr. Hartmut Ehrlich, at the BIO Europe 2015 conference, to be held in Munich on November 2nd to 4th, and at the Deutsches Eigenkapitalforum to be held in Frankfurt on November 23rd and 24th.  Prof. Ehrlich will make presentations on ABIVAX’s current development program and strategy at both events.

Press contacts

Caroline Carmagnol 

abivax@alizerp.com

+ 33 6 64 18 99 59 or
+ 33 1 44 54 36 65

 Standard: +33 1 53 83 08 41